Greenland Mines Ltd (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.
This patent grant is a significant milestone for Greenland Mines, as it provides robust intellectual property protection in Australia, a key market for biotech innovation. The Klotho gene therapy platform has the potential to address unmet medical needs in neuromuscular diseases, particularly ALS, a progressive neurodegenerative disease with limited treatment options. The patent covers multiple aspects of the technology, including gene therapy constructs and delivery systems, which could be crucial for advancing the KLTO-202 program toward clinical trials.
Greenland Mines operates through two divisions: Mining and Biotech. The Mining division focuses on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland. The Biotech division is centered on the Klotho platform, with KLTO‑202 as the primary indication for ALS. The company’s strategy involves building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The patent grant is expected to bolster investor confidence in Greenland Mines’ biotech pipeline. According to the press release, the full details are available at https://nnw.fm/PVbbH. Additionally, the latest news and updates relating to GRML can be found in the company’s newsroom at https://nnw.fm/GRML.
This development underscores the potential of gene therapy in treating debilitating neuromuscular conditions and highlights Greenland Mines’ dual focus on mining and biotech. The Australian patent adds to the company’s growing IP portfolio, which could pave the way for further advancements in the KLTO-202 program and other indications. As the company continues to progress its biotech initiatives, this patent serves as a foundational asset for future research and development efforts.
